ArticleThe Journal of dermatology2025
Biologic Therapy and Malignancy Risk in Psoriasis: A Retrospective Cohort Study.
Article in The Journal of dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The long-term impact of biologic therapy on malignancy risk in patients with psoriasis remains unclear. Given the chronic nature of psoriasis and the increasing use of biologics, understanding their long-term safety profile is crucial. This study aimed to compare the incidence of malignancy between patients receiving continuous biologic therapy and those treated with topical monotherapy. We retrospectively analyzed 446 patients with psoriasis treated at a single center between May 2010 and March 2023 (biologic therapy: n = 226; topical monotherapy: n = 220). Malignancy incidence was estimated using the Kaplan-Meier method. Multivariable Cox proportional hazards regression with propensity score adjustment was employed to control for confounding variables. Subgroup analysis was performed within the biologic-treated cohort to identify additional malignancy risk factors. Malignancies occurred in 11.2% (50/446) of patients, with rates of 4.4% (10/226) in the biologic therapy group and 18.2% (40/220) in the topical therapy group (p < 0.0001). Kaplan-Meier analysis demonstrated a significantly lower cumulative incidence of malignancy in the biologic group (p = 0.0035, log-rank test). Cox regression confirmed that biologic therapy was associated with a significantly reduced malignancy risk (hazard ratio [HR]: 0.316; 95% confidence interval [CI]: 0.119-0.841; p = 0.0211). Notably, subgroup analysis using Cox regression within the biologic-treated cohort revealed that family history of malignancy was significantly associated with an increased risk of malignancy (HR: 9.01; 95% CI: 1.69-4.87; p < 0.05). In conclusion, biologic therapy was associated with a significantly lower risk of malignancy in patients with psoriasis compared to topical monotherapy. Furthermore, family history of malignancy may represent an independent risk factor for malignancy among biologic-treated patients. These findings underscore the importance of individualized cancer risk assessment when selecting treatment strategies and highlight the need for further prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.